President Donald Trump has thrown down the gauntlet to Big Pharma, demanding that 17 leading drugmakers slash U.S. prices within 60 days. This bold move signals a renewed push to tackle the staggering cost of prescription drugs that burden American families.
According to CNBC, Trump posted individual letters on Truth Social to companies like Eli Lilly, Pfizer, Merck, and Novo Nordisk, urging immediate action. He warned of deploying every tool available to protect families from what he calls abusive pricing if they fail to comply by Sept. 29.
The initiative follows Trump's executive order in May reviving the "most favored nation" policy, which ties U.S. drug prices to lower costs abroad. With American prices often two to three times higher than in other developed nations, this is a direct challenge to an industry long criticized for prioritizing profit over patients.
Trump's letters to the 17 drugmakers, including heavyweights like Johnson & Johnson and Bristol Myers Squibb, pull no punches. He dismissed their past proposals as mere blame-shifting and demands for billions in handouts, refusing to entertain more of the same.
Instead, he insists on commitments that deliver immediate relief to Americans facing inflated costs and end the trend of other nations benefiting from U.S. innovation without fair contribution. His vision of collaboration sounds reasonable, but it’s a clear ultimatum to an industry unaccustomed to such pressure.
Trump's frustration is palpable when he states that drugmakers have offered "more of the same," a line that rings true for many who’ve watched prices soar while excuses pile up. If companies think they can keep dodging accountability, they’re underestimating a leader who thrives on shaking up entrenched systems.
The president outlined precise steps, starting with offering existing medicines at the lowest prices seen in other developed countries to every Medicaid patient. He also wants contracts ensuring Medicare, Medicaid, and commercial payers get these "most favored nation" rates on all new drugs from launch onward.
Further, Trump called on companies to negotiate tougher with foreign nations he accuses of freeloading, using U.S. trade policy to back them up. Any increased revenue from abroad, he insists, must be redirected to lower costs for American patients and taxpayers through formal agreements.
He also pushed for direct-to-consumer or business sales models to cut out middlemen, ensuring all Americans have access to the same low prices offered to third-party payers. This isn’t just tinkering around the edges; it’s a fundamental rethink of how drugs are priced and sold.
The pharmaceutical industry didn’t take long to respond, with PhRMA’s Alex Schriver warning that "importing foreign price controls would undermine American leadership." That’s a predictable dodge, sidestepping the reality that leadership means little when families can’t afford life-saving meds.
Shares of several companies, including Bristol Myers Squibb, Novo Nordisk, and Sanofi, took a hit after the announcement, with some dropping as much as 8%. This market reaction shows Wall Street knows Trump isn’t bluffing, even as firms like Pfizer and Novartis claim they’re open to solutions.
PhRMA’s suggestion to rein in middlemen and make foreign countries pay their share sounds fair, but it’s a convenient deflection from their own role in price gouging. If they’re serious about reform, they’ll need more than vague promises to meet Trump’s deadline.
Trump’s latest move, coupled with planned tariffs on imported pharmaceuticals, has drugmakers on edge, especially as some like AstraZeneca already float price cuts and direct sales. It’s a sign the pressure is working, even if the road ahead remains contentious.
For too long, Americans have borne the cost of innovation while others reap the benefits, a disparity Trump is determined to end. His insistence on immediate relief isn’t just rhetoric; it’s a lifeline for those crushed by medical bills.
This fight is far from over, but it’s a refreshing shift to see a leader hold an industry accountable rather than bowing to its lobbyists. If Big Pharma wants to avoid the full arsenal Trump threatens, they’d better come to the table with real concessions, not recycled excuses.
